vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix Maciag PC, et al. Vaccine, 2009, 27(30):3975-3983. Therapeutic cancer vaccines... bench to clinic Singh R and Wallecha A. Hum Vaccine. 2011. 7(5). Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy Paterson Y..., Guirnalda PD, Wood LM. Semin Immunol. 2010 Jun;22(3):183-9. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment Shahabi V, et al. Bioeng Bugs. 2010...

when combined with standard chemotherapy and radiation treatment for anal cancer. National Cancer Institute Vaccine Section Advaxis has a Collaborative Research and Development... Agreement (CRADA) with the Vaccine Section of the National Cancer Institute for the development of Advaxis immunotherapies. NCI will use different in vitro and in vivo models...Partners ADVAXIS Skip to content ADVAXISdeveloping the next generation of cancer immunotherapies About Us Corporate Overview Management Team Board of Directors Science Mechanism...

Archive Skip to content ADVAXISdeveloping the next generation of cancer immunotherapies About Us Corporate Overview Management Team Board of Directors Science Mechanism of Action... Francisco, CA Website Presentation Slides San Antonio Breast Cancer Symposium 2012 Poster presentation by Dr. Anu Wallecha, Director of Research and Development at Advaxis Poster P4...-04-05 titled Listeria monocytogenes based bivalent Lm-LLO immunotherapy for the treatment of HER2/neu positive and triple negative breast cancer and its impact on immunosuppression...